Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

OBJECTIVE: The purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as the first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) on health and economic outcomes in China. METHODS: A Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qilin, Wu, Pan, He, Xucheng, Ding, Yufeng, Shu, Yamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671697/
https://www.ncbi.nlm.nih.gov/pubmed/34926306
http://dx.doi.org/10.3389/fonc.2021.790373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671697/
https://www.ncbi.nlm.nih.gov/pubmed/34926306
http://dx.doi.org/10.3389/fonc.2021.790373

Ejemplares similares